Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153942 | 0.84 | MET (0.43) | METCSNK1ECLK1DYRK1ADYRK2 | |
| SCHEMBL3244677 | 0.78 | MET (0.45) | MET | |
| SCHEMBL3244679 | 0.78 | MET (0.43) | METCSNK1ECLK1DYRK1ADYRK2 | |
| SCHEMBL3253410 | 0.75 | MET (0.42) | MET | |
| SCHEMBL3255432 | 0.74 | MET (0.41) | MET | |
| SCHEMBL4162519 | 0.70 | DAO (0.42) | — | |
| Propionic Acid SCHEMBL4153947 | 0.69 | MET (0.45) | METAKR1B1 | |
| SCHEMBL4171781 | 0.67 | TBXAS1 (0.39) | — | |
| SCHEMBL4157925 | 0.67 | PNP (0.37) | — | |
| SCHEMBL4155191 | 0.65 | HPGD (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | MET 1215/4885AHR 3297/4885CSNK1E 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.